Farallon Capital Management LLC Invests $45.01 Million in Nektar Therapeutics $NKTR

Farallon Capital Management LLC acquired a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 791,000 shares of the biopharmaceutical company’s stock, valued at approximately $45,008,000. Farallon Capital Management LLC owned about 3.89% of Nektar Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of NKTR. AQR Capital Management LLC raised its holdings in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 2,807,595 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Nektar Therapeutics by 446.9% during the third quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after buying an additional 354,842 shares during the last quarter. Emerald Advisers LLC bought a new stake in shares of Nektar Therapeutics during the third quarter valued at approximately $18,393,000. Jefferies Financial Group Inc. bought a new stake in shares of Nektar Therapeutics during the third quarter valued at approximately $17,252,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in Nektar Therapeutics in the 3rd quarter worth approximately $13,269,000. 75.88% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Jonathan Zalevsky sold 3,867 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total value of $137,935.89. Following the transaction, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. This trade represents a 15.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the transaction, the chief executive officer directly owned 75,489 shares in the company, valued at approximately $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 4,470 shares of company stock valued at $181,955 in the last three months. 3.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NKTR. BTIG Research upped their price objective on Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Oppenheimer restated an “outperform” rating and issued a $140.00 price target on shares of Nektar Therapeutics in a research note on Friday. HC Wainwright upped their price target on Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $133.43.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations: EPS loss of ($1.78) topped consensus and revenue of $21.8M substantially exceeded estimates; management highlighted promising clinical data and near-term plans for rezpeg Phase III studies in atopic dermatitis (timing noted for Q2 2026). Nektar Reports Fourth-Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Earnings call and analyst coverage reinforced the upside: call transcripts and press coverage flagged promising Phase 2b/clinical takeaways that appear to be driving bullish investor sentiment and volume today. Earnings Call Transcript
• Neutral Sentiment: Balance-sheet snapshot: cash and marketable securities were $245.8M at year-end (down from $269.1M a year earlier) — provides runway but still limited given development-stage spending; watch cash burn guidance and upcoming Phase III cost needs. Financial Results / Cash Position
• Negative Sentiment: Multiple law firms have filed or announced securities-fraud investigations and class action notices covering the Feb 26–Dec 15, 2025 period; several firms are soliciting lead-plaintiff motions with a May 5, 2026 deadline — litigation could lead to legal costs, management distraction and settlement risk. Rosen Law Firm Notice Pomerantz Filing

Nektar Therapeutics Price Performance

Shares of NKTR stock opened at $73.25 on Monday. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -7.18 and a beta of 1.16. Nektar Therapeutics has a 1 year low of $6.45 and a 1 year high of $77.00. The firm has a fifty day moving average price of $53.50 and a 200-day moving average price of $53.40.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The company had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%. Equities research analysts expect that Nektar Therapeutics will post -0.72 EPS for the current year.

Nektar Therapeutics Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.